DDInter624 DDInter1731
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3.
Efavirenz {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Sunitinib
Efavirenz {u} (Compound) upregulates {v} (Gene) IKBKB
IKBKB {u} (Gene) is upregulated by {v} (Compound) Sunitinib
Efavirenz {u} (Compound) downregulates {v} (Gene) RFC2
RFC2 {u} (Gene) is downregulated by {v} (Compound) Sunitinib
Efavirenz {u} (Compound) causes {v} (Side Effect) Menopausal symptoms
Menopausal symptoms {u} (Side Effect) is caused by {v} (Compound) Sunitinib
Efavirenz {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) covaries with {v} (Gene) PTK2B
PTK2B {u} (Gene) is bound by {v} (Compound) Sunitinib
Efavirenz {u} (Compound) upregulates {v} (Gene) IKBKB
IKBKB {u} (Gene) interacts with {v} (Gene) MAP3K3
MAP3K3 {u} (Gene) is bound by {v} (Compound) Sunitinib
Efavirenz {u} (Compound) downregulates {v} (Gene) RFC2
RFC2 {u} (Gene) is regulated by {v} (Gene) GRK4
GRK4 {u} (Gene) is bound by {v} (Compound) Sunitinib
Efavirenz {u} (Compound) causes {v} (Side Effect) Menopausal symptoms
Menopausal symptoms {u} (Side Effect) is caused by {v} (Compound) Pazopanib
Pazopanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sunitinib
Efavirenz {u} (Compound) causes {v} (Side Effect) Cardiac failure congestive
Cardiac failure congestive {u} (Side Effect) is caused by {v} (Compound) Metoclopramide
Metoclopramide {u} (Compound) resembles {v} (Compound) Sunitinib
Efavirenz {u} (Compound) causes {v} (Side Effect) Renal failure
Renal failure {u} (Side Effect) is caused by {v} (Compound) Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sunitinib
Efavirenz (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sunitinib (Compound)
Efavirenz (Compound) upregulates IKBKB (Gene) and IKBKB (Gene) is upregulated by Sunitinib (Compound)
Efavirenz (Compound) downregulates RFC2 (Gene) and RFC2 (Gene) is downregulated by Sunitinib (Compound)
Efavirenz (Compound) causes Menopausal symptoms (Side Effect) and Menopausal symptoms (Side Effect) is caused by Sunitinib (Compound)
Efavirenz (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) covaries with PTK2B (Gene) and PTK2B (Gene) is bound by Sunitinib (Compound)
Efavirenz (Compound) upregulates IKBKB (Gene) and IKBKB (Gene) interacts with MAP3K3 (Gene) and MAP3K3 (Gene) is bound by Sunitinib (Compound)
Efavirenz (Compound) downregulates RFC2 (Gene) and RFC2 (Gene) is regulated by GRK4 (Gene) and GRK4 (Gene) is bound by Sunitinib (Compound)
Efavirenz (Compound) causes Menopausal symptoms (Side Effect) and Menopausal symptoms (Side Effect) is caused by Pazopanib (Compound) and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Efavirenz (Compound) causes Cardiac failure congestive (Side Effect) and Cardiac failure congestive (Side Effect) is caused by Metoclopramide (Compound) and Metoclopramide (Compound) resembles Sunitinib (Compound)
Efavirenz (Compound) causes Renal failure (Side Effect) and Renal failure (Side Effect) is caused by Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Sunitinib